123 related articles for article (PubMed ID: 8819302)
1. Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues.
Lewis DF; Lake BG
Xenobiotica; 1996 Jul; 26(7):723-53. PubMed ID: 8819302
[TBL] [Abstract][Full Text] [Related]
2. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.
Lewis DF; Lake BG; George SG; Dickins M; Eddershaw PJ; Tarbit MH; Beresford AP; Goldfarb PS; Guengerich FP
Toxicology; 1999 Nov; 139(1-2):53-79. PubMed ID: 10614688
[TBL] [Abstract][Full Text] [Related]
3. cDNA cloning and characterization of feline CYP1A1 and CYP1A2.
Tanaka N; Miyasho T; Shinkyo R; Sakaki T; Yokota H
Life Sci; 2006 Nov; 79(26):2463-73. PubMed ID: 17097115
[TBL] [Abstract][Full Text] [Related]
4. Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.
Sridhar J; Goyal N; Liu J; Foroozesh M
Molecules; 2017 Jul; 22(7):. PubMed ID: 28698457
[TBL] [Abstract][Full Text] [Related]
5. Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure.
Lewis DF; Lake BG; Dickins M; Ueng YF; Goldfarb PS
Xenobiotica; 2003 Mar; 33(3):239-54. PubMed ID: 12637242
[TBL] [Abstract][Full Text] [Related]
6. Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene-induced rats.
Spatzenegger M; Horsmans Y; Verbeeck RK
Pharmacol Toxicol; 2000 Feb; 86(2):71-7. PubMed ID: 10728918
[TBL] [Abstract][Full Text] [Related]
7. CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation.
Uckun FM; Thoen J; Chen H; Sudbeck E; Mao C; Malaviya R; Liu XP; Chen CL
Drug Metab Dispos; 2002 Jan; 30(1):74-85. PubMed ID: 11744615
[TBL] [Abstract][Full Text] [Related]
8. Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism.
Huang Q; Deshmukh RS; Ericksen SS; Tu Y; Szklarz GD
Drug Metab Dispos; 2012 Dec; 40(12):2324-31. PubMed ID: 22949628
[TBL] [Abstract][Full Text] [Related]
9. Oxidative inactivation of cytochrome P-450 1A (CYP1A) stimulated by 3,3',4,4'-tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1As.
Schlezinger JJ; White RD; Stegeman JJ
Mol Pharmacol; 1999 Sep; 56(3):588-97. PubMed ID: 10462547
[TBL] [Abstract][Full Text] [Related]
10. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1.
Doostdar H; Burke MD; Mayer RT
Toxicology; 2000 Apr; 144(1-3):31-8. PubMed ID: 10781868
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries.
Lewis DF; Dickins M; Eddershaw PJ; Tarbit MH; Goldfarb PS
Drug Metabol Drug Interact; 1999; 15(1):1-49. PubMed ID: 10707112
[TBL] [Abstract][Full Text] [Related]
12. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1996 Oct; 26(10):1067-86. PubMed ID: 8905920
[TBL] [Abstract][Full Text] [Related]
13. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 (CYP) mutants and substrate-specificity alterations: segment-directed mutagenesis applied to human CYP1A1.
Urban P; Jobert AS; Lainé R; Pompon D
Biochem Soc Trans; 2001 May; 29(Pt 2):128-35. PubMed ID: 11356140
[TBL] [Abstract][Full Text] [Related]
15. Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102.
Lewis DF; Lake BG
Xenobiotica; 1999 Aug; 29(8):763-81. PubMed ID: 10553718
[TBL] [Abstract][Full Text] [Related]
16. Ensemble modeling of substrate binding to cytochromes P450: analysis of catalytic differences between CYP1A orthologs.
Prasad JC; Goldstone JV; Camacho CJ; Vajda S; Stegeman JJ
Biochemistry; 2007 Mar; 46(10):2640-54. PubMed ID: 17300179
[TBL] [Abstract][Full Text] [Related]
17. Access channels to the buried active site control substrate specificity in CYP1A P450 enzymes.
Urban P; Truan G; Pompon D
Biochim Biophys Acta; 2015 Apr; 1850(4):696-707. PubMed ID: 25529298
[TBL] [Abstract][Full Text] [Related]
18. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP.
Murray BP; Edwards RJ; Murray S; Singleton AM; Davies DS; Boobis AR
Carcinogenesis; 1993 Apr; 14(4):585-92. PubMed ID: 8472319
[TBL] [Abstract][Full Text] [Related]
19. The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes.
Ueng YF; Jan WC; Lin LC; Chen TL; Guengerich FP; Chen CF
Drug Metab Dispos; 2002 Mar; 30(3):349-53. PubMed ID: 11854157
[TBL] [Abstract][Full Text] [Related]
20. A novel gender-related difference in the constitutive expression of hepatic cytochrome P4501A subfamily enzymes in Meishan pigs.
Kojima M; Sekimoto M; Degawa M
Biochem Pharmacol; 2008 Mar; 75(5):1076-82. PubMed ID: 18068149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
